Tencent Soars Most Since 2022 On Report It's Set To Launch AI Agent For China's Most Used App Tencent shares jumped the most since late 2022 after an FT report that the Chinese company was testing a prototype AI agent for WeChat, China’s most widely used app for everything from messaging and social media to ride-hailing and payments, fueled optimism about the company’s artificial intelligence effo...
Tencent Soars Most Since 2022 On Report It's Set To Launch AI Agent For China's Most Used App Tencent shares jumped the most since late 2022 after an FT report that the Chinese company was testing a prototype AI agent for WeChat, China’s most widely used app for everything from messaging and social media to ride-hailing and payments, fueled optimism about the company’s artificial intelligence efforts. The Chinese internet giant plans to begin a compliance process for a public launch of the agent as soon as this month, the Financial Times reported, citing sources. After that, Tencent plans to test the agent on a small group of outside users before initiating a phased rollout, the newspaper said. Shares of Tencent closed up 10.5%, its biggest jump since November 2022, with turnover at the highest in more than a year. The stock gave a boost to the Hang Seng Tech Index, which rose 4.7%. Users will be able to access the chat box for the AI agent by swiping right on the main WeChat screen, according to a person who has seen an early demonstration. They can then enter instructions for the agent to automatically tap into WeChat’s millions of mini-apps, the bedrock of the app’s broad functionality, and complete tasks such as finding a café and ordering a drink based on certain flavor and price requirements. A successful introduction of an AI agent for the popular WeChat service would mark a step forward for Tencent’s bid to catch up to rivals in the rapidly emerging technology. While Tencent has vowed to at least double investments in the field to more than 36 billion yuan ($5.3 billion) this year, it trails peers like ByteDance and Alibaba in both user adoption and advances in developing state-of-the-art large language models. “Tencent has been a huge underperformer this year because market perceives it as an AI laggard,” said Vey-Sern Ling, managing director at Union Bancaire Privee. “The AI agent, if successful, could change such a perception. Even though there’s very lit...
AUSTIN, Texas, June 02, 2026--Whole Foods Market today opened applications for its 2026 Local and Emerging Accelerator Program (LEAP), reinforcing the company’s commitment to supporting innovative local and emerging brands. Launched in 2022, the program provides mentorship opportunities to a select group of brands not yet on the shelves of Whole Foods Market. Selected brands receive coaching from ...
AUSTIN, Texas, June 02, 2026--Whole Foods Market today opened applications for its 2026 Local and Emerging Accelerator Program (LEAP), reinforcing the company’s commitment to supporting innovative local and emerging brands. Launched in 2022, the program provides mentorship opportunities to a select group of brands not yet on the shelves of Whole Foods Market. Selected brands receive coaching from Whole Foods Market and industry experts, tailored educational programming, and the potential for dir
IceCure Medical ( ICCM ) announced on Tuesday that it will complete a 1-for-30 reverse stock split on June 4, 2026, while continuing to trade under the ticker ICCM. The move is aimed at lifting the share price above Nasdaq's $1 minimum bid requirement and helping the company maintain its Nasdaq listing. The company has until November 9, 2026, to regain compliance. Following the reverse split, the ...
IceCure Medical ( ICCM ) announced on Tuesday that it will complete a 1-for-30 reverse stock split on June 4, 2026, while continuing to trade under the ticker ICCM. The move is aimed at lifting the share price above Nasdaq's $1 minimum bid requirement and helping the company maintain its Nasdaq listing. The company has until November 9, 2026, to regain compliance. Following the reverse split, the company's outstanding share count will fall from 84.2M to about 2.8M shares. The reverse split will also adjust stock options, warrants, and equity awards, while shareholders' ownership stakes will remain largely unchanged. The stock is trading 19% lower at $0.16. Source: Press Release More on IceCure Medical IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript IceCure Medical Ltd (ICCM) Q4 2025 Earnings Call Transcript IceCure gets 180-day Nasdaq extension to regain bid price compliance IceCure Medical GAAP EPS of $0.06, revenue of $911M Seeking Alpha’s Quant Rating on IceCure Medical
Thomas Barwick/DigitalVision via Getty Images Investment overview I wrote about KE Holdings ( BEKE ) previously with a hold rating as I was waiting for more evidence that BEKE’s growth will normalize. Looking at the Q1 2026 results, I lean more bullish, but I am not ready to upgrade the stock yet. The key update here is that BEKE showed profit can recover even while revenue is still weak. Existing...
Thomas Barwick/DigitalVision via Getty Images Investment overview I wrote about KE Holdings ( BEKE ) previously with a hold rating as I was waiting for more evidence that BEKE’s growth will normalize. Looking at the Q1 2026 results, I lean more bullish, but I am not ready to upgrade the stock yet. The key update here is that BEKE showed profit can recover even while revenue is still weak. Existing homes also look less broken, and the newer businesses are being run with better discipline. That said, revenue is still declining, and new homes remain a large drag. For now, I stay on hold, but with a more positive bias. Thoughts on 1Q 2026 earnings BEKE’s 1Q26 revenue was still weak, but profit came in better than I thought. Total GTV was down ~16% y/y to RMB711.7 billion, and net revenue was down 19% y/y to RMB18.9 billion. The decline came mainly from lower revenue in new home and existing home transaction services, both of which were coming off a high base last year. By segments, existing home transaction services revenue fell ~11% y/y to RMB6.1 billion, with GTV down ~8% y/y to RMB534.4 billion. Within the segment, commission revenue fell ~14% y/y to RMB4.8 billion, as GTV served by Lianjia stores fell ~15% y/y. Platform service, franchise service, and other value-added service revenue grew ~4% y/y to RMB1.34 billion. As for new home transaction services, this remained the weakest segment. Revenue fell 37% y/y to RMB5.1 billion, while GTV fell ~37% y/y to RMB145.9 billion. GTV from transactions facilitated through connected agents, dedicated sales teams, and other channels also fell 37.5% y/y. As for Lianjia, GTV here fell 35.4% y/y. Clearly, this segment was still a major drag. Home renovation and furnishing revenue also fell ~21% y/y to RMB2.3 billion, and the decline was tied to BEKE optimizing customer acquisition channels and slowing down certain non-brokerage channels. Elsewhere, home rental services revenue fell 1.5% y/y to RMB5 billion. This was mainly becaus...
Alexey_Fedoren BNP Paribas started coverage of Nebius ( NBIS ) with a Neutral rating and a $255 price target noting that the recent share spike limits upside. Shares of the Dutch AI infrastructure solutions provider rose about 4% on Tuesday. Analysts led by Stefan Slowinski said that Nebius shares have rallied over 216% year-to-date, emerging as one of the market’s preferred ways to play the AI co...
Alexey_Fedoren BNP Paribas started coverage of Nebius ( NBIS ) with a Neutral rating and a $255 price target noting that the recent share spike limits upside. Shares of the Dutch AI infrastructure solutions provider rose about 4% on Tuesday. Analysts led by Stefan Slowinski said that Nebius shares have rallied over 216% year-to-date, emerging as one of the market’s preferred ways to play the AI compute scarcity theme. Strong execution, exposure to shorter-duration contracts that benefit from rising graphics processing unit, or GPU, rental pricing, and strategic monetizable assets (its nearly 25% stake in ClickHouse) have supported the re-rating, the analysts added. "However, our Nebius datacenter model suggesting only modest upside to management’s 2026 ARR [Annual Recurring Revenue] outlook despite recent price increases and the mix benefit from newer NVIDIA GPUs. In turn, we believe expectations reflect a continuation of favorable pricing dynamics and near-flawless execution, leaving the near-term risk-reward less compelling in our view," Slowinski and his team. BNP Paribas also began coverage of Nebius' rival CoreWeave ( CRWV ) with an Outperform rating and $192 price target. More on Nebius Group Nebius: Ballooning Upside Potential The Smartest AI Money Is Buying Nebius Nebius: Riding Powerful Demand Volume And Pricing Tailwinds Nebius jumps as AI-linked hedge fund discloses passive stake Leopold Aschenbrenner’s Situational Awareness fund discloses 5.6% stake in Nebius Group
Dorman Products ( DORM ) on Tuesday said it would commence a private offering of $450M aggregate principal amount of senior notes due 2034. Dorman intends to use the net proceeds from the offering to repay indebtedness under existing credit facilities and, to the extent of any remainder, for general corporate purposes. DORM +1.31% to $124.32. Source: Press Release More on Dorman Products Dorman Pr...
Dorman Products ( DORM ) on Tuesday said it would commence a private offering of $450M aggregate principal amount of senior notes due 2034. Dorman intends to use the net proceeds from the offering to repay indebtedness under existing credit facilities and, to the extent of any remainder, for general corporate purposes. DORM +1.31% to $124.32. Source: Press Release More on Dorman Products Dorman Products, Inc. 2026 Q1 - Results - Earnings Call Presentation Dorman Products, Inc. (DORM) Q1 2026 Earnings Call Transcript Dorman Products: Mispriced Ahead Of Q1 Earnings Dorman reaffirms 2026 outlook for 7% to 9% net sales growth and $8.10 to $8.50 adjusted EPS as tariff costs ease through the year Seeking Alpha’s Quant Rating on Dorman Products
Thomas Barwick/DigitalVision via Getty Images A Quick Take On Kardigan's IPO Kardigan, Inc. ( KARD ) has filed to raise development funding in an IPO, according to an SEC registration statement . The company is a clinical-stage biopharma firm developing treatments for cardiovascular diseases. It has shown positive trial results, appears to be well capitalized, and is backed by high-quality life sc...
Thomas Barwick/DigitalVision via Getty Images A Quick Take On Kardigan's IPO Kardigan, Inc. ( KARD ) has filed to raise development funding in an IPO, according to an SEC registration statement . The company is a clinical-stage biopharma firm developing treatments for cardiovascular diseases. It has shown positive trial results, appears to be well capitalized, and is backed by high-quality life science venture capital firm investors, so the IPO should be in demand from institutional life science investors. I'll provide a final opinion when we get more information about valuation from management. Kardigan Overview and Development Efforts Kardigan is developing a pipeline of medicines to treat various serious cardiovascular diseases that don't have approved treatments. Its lead program, Danicamtiv, is in Phase 2b/3 trials for the treatment of genetic dilated cardiomyopathy [DCM], with topline data expected in the first half of 2027. The graphic below shows the current status of its treatment candidates and stage of clinical trials: SEC Danicamtiv was initially developed by MyoKardia and BMS Co., and the company's other candidates were originally developed by third parties as well. So, the firm has in-licensed the IP and is dependent on initial trial data from each of the parties involved in the earlier development activities. A key element of Kardigan's approach is to utilize its Prolario AI-enabled tool platform to enhance the design and execution of its trial efforts through better patient identification and enrollment and data collection. The risks to this approach are that the FDA may not recognize or accept the company's digital clinical endpoints collected through its system. Kardigan is led by co-founder, Chief Executive Officer, and Chairman Tassos Gianakakos, who also co-founded Prolario and was CEO and President of MyoKardia when it was acquired by Bristol-Myers Squibb ( BMY ). The company has recorded $634 million in fair market value investment from invest...
Zoom Communications ( ZM ) was in the spotlight on Tuesday as HSBC upped its price target on the tech company, stating its enterprise momentum is “underpriced” by investors. “We see upside given that Zoom is moving beyond a mature video conferencing platform into a broader AI-enabled communications platform,” analyst Sameer Lam wrote in a note to clients. “Furthermore, we see that growth is increa...
Zoom Communications ( ZM ) was in the spotlight on Tuesday as HSBC upped its price target on the tech company, stating its enterprise momentum is “underpriced” by investors. “We see upside given that Zoom is moving beyond a mature video conferencing platform into a broader AI-enabled communications platform,” analyst Sameer Lam wrote in a note to clients. “Furthermore, we see that growth is increasingly being driven by newer vectors, with Phone ARR growing mid-teens, ZCX growing high-double digit and AI Companion paid MAUs up 184% y-o-y. Combined with a strong margin profile, cUSD7.7bn of cash, no debt, and a constructive pace of share repurchases, we think that the company has a premium brand and is stacking growth on top of a solid financial footing. Given shares trading at [roughly] 16x CY26 PE, we view the risk reward as compelling.” Lam raised his price target on Zoom to $133 from $107 and reiterated his Buy rating. Shares of Zoom fell 1.4% in early trading on Tuesday. More on Zoom Communications Zoom Communications, Inc. 2027 Q1 - Results - Earnings Call Presentation Zoom Communications, Inc. (ZM) Q1 2027 Earnings Call Transcript Zoom Keeps Generating Cash While Growth Remains Elusive Zoom gains momentum on new products; provides conservative guide: Citi Zoom soars after Q1 results see largely bullish views from analysts
Venezuela has retained Hogan Lovells US LLP as legal counsel for what is expected to be one of the largest sovereign debt restructurings in decades. The hiring — made public in a filing published by the Justice Department’s Foreign Agents Registration Act unit on Tuesday — comes less than a month after the government announced it was starting the process to rework an estimated $170 billion of debt...
Venezuela has retained Hogan Lovells US LLP as legal counsel for what is expected to be one of the largest sovereign debt restructurings in decades. The hiring — made public in a filing published by the Justice Department’s Foreign Agents Registration Act unit on Tuesday — comes less than a month after the government announced it was starting the process to rework an estimated $170 billion of debt that’s been in default since 2017. The law firm, which has headquarters in Washington and London, said in an email that it has a long history of working with the country and was hired to for both the restructuring and to provide assistance on government relations in the US. Norm Coleman , a former US Senator from Minnesota who was a member of the Foreign Relations Committee before joining Hogan Lovells in 2011, will represent Venezuela for the firm, according to people familiar with the matter. Hogan Lovells was previously hired by Venezuela’s US embassy in 2014 to provide lobbying services in Washington. Officials at Venezuela’s communications ministry didn’t immediately respond to request for comments. Dentons Europe LLP will remain Venezuela’s international legal counsel, advising the interim administration of Delcy Rodriguez on oil and mining contracts. Investors have piled into the oil-rich nation’s bonds after the US captured President Nicolas Maduro in January. The government, now headed by former Vice President Delcy Rodriguez, has worked closely with Washington, sparking optimism that it would open the path for a long-awaited restructuring. Read more: A 220% Bond Rally Snaps as Venezuela Euphoria Gets Reality Check Government bonds have gained more than 80% this year, with notes due in 2027 trading at roughly 52 cents on the dollar. That implies investors are expected to recover about 30% of their overall claims, once accrued unpaid interest is included. The US Treasury in early May authorized the appointments of legal counsel and financial consultants for the pro...
J. Michael Jones/iStock Editorial via Getty Images Shares of Signet Jewelers Limited ( SIG ) have been a solid performer over the past year, up about 27%. However, the stock is also down about 15% from its highs. Essentially, shares have been caught between the fact that consumer demand has been relatively resilient and fears that affordability challenges may eventually pressure discretionary spen...
J. Michael Jones/iStock Editorial via Getty Images Shares of Signet Jewelers Limited ( SIG ) have been a solid performer over the past year, up about 27%. However, the stock is also down about 15% from its highs. Essentially, shares have been caught between the fact that consumer demand has been relatively resilient and fears that affordability challenges may eventually pressure discretionary spending. At the same time, shares are relatively cheap, providing opportunities for accretive buybacks. On Tuesday, the company reported solid earnings , sending shares up 7% in early trading. I last covered shares in March , rating the stock a “buy,” given valuation, but that call has not played out, with shares losing 5% since then. With updated financials, now is a good time to revisit Signet to see if shares can rally or are likely to remain structurally cheap. Seeking Alpha Stable sales and improving operating leverage highlight Q1 In the company’s fiscal first quarter , Signet Jewelers earned $1.56, which beat estimates by $0.18 as revenue grew 1% to $1.56 billion. Earnings were up 32% from last year, thanks to better margins and the benefits of a lower share count. Same-store sales grew 1.8%, led by positive Valentine’s Day. With Mother’s Day also being positive, the company is positioned to generate some growth in the second quarter as well. Pricing was up 5%, driving the sales growth, as the company has been effective at passing on much of its higher material costs to customers. Adjusted gross profit declined by $10 million to $589 million as these price increases were more than fully offset by higher input costs, partly driven by tariffs, as well as higher gold prices ( XAUUSD:CUR ). We may see some moderation in margin pressure going forward given declining tariff pressure. Thanks to higher sales and efficiency efforts, we saw material operating leverage, with SG&A at 32.8% of sales, better than the 34.1% reported last year. As a result, adjusted operating income gr...
Robert Way Victoria’s Secret ( VSXY ) enjoyed a strong start to the year with first quarter results that exceeded Wall Street’s expectations, fueled by increased customer acquisition, less promotional pricing, and strength across categories, channels, and geographies. The results led the company to raise its sales outlook for the year and set second-quarter guidance that was better than anticipate...
Robert Way Victoria’s Secret ( VSXY ) enjoyed a strong start to the year with first quarter results that exceeded Wall Street’s expectations, fueled by increased customer acquisition, less promotional pricing, and strength across categories, channels, and geographies. The results led the company to raise its sales outlook for the year and set second-quarter guidance that was better than anticipated. “We are increasingly confident in the trajectory of the business. Our teams are executing with greater precision and agility, Victoria’s Secret, PINK, and Beauty are gaining cultural relevance and expanding their customer files, and we have a strong pipeline of product launches, partnerships, and brand moments ahead. We believe we are well positioned to continue building momentum and creating shareholder value,” said Victoria’s Secret CEO Hillary Super. Driven by a 13% increase in comparable store sales and a 15% increase in total sales, the retailer earned a profit of $0.60 per share, significantly above the company’s guidance of $0.20 to $0.30 per share and nearly double Wall Street’s expectations. In the same quarter last year, Victoria’s Secret ( VSXY ) earned a more modest profit of $0.09 per share. For the current quarter, net sales are now seen between $1.59B and $1.615B, an increase of nearly 10% at the midpoint from a year ago and above $1.56B estimates. For FY26, sales guidance was raised 2.6% at the midpoint to a new range of $7.030B and $7.130B versus $6.96B estimates. Shares of Victoria’s Secret are now trading under the new ticker symbol of VSXY and with a gain of more than 46% at Tuesday’s open. More on Victoria’s Secret Victoria's Secret & Co. 2026 Q1 - Results - Earnings Call Presentation Victoria's Secret: Upgrading To A Cautious Hold, Due To The Sustained Demand Victoria's Secret: Bull Case Is Playing Out Nicely Victoria’s Secret Non-GAAP EPS of $0.60 beats by $0.28, revenue of $1.56B beats by $40M Victoria’s Secret Q1 2027 Earnings Preview